TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of EUR 4.59 billion. The enterprise value is 4.57 billion.

Market Cap	4.59B
Enterprise Value	4.57B

Important Dates

The last earnings date was Monday, May 5, 2025.

Earnings Date	May 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	145.82M
Shares Outstanding	n/a
Shares Change (YoY)	+9.66%
Shares Change (QoQ)	+1.58%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	148.09M

Valuation Ratios

The trailing PE ratio is 126.67 and the forward PE ratio is 24.62.

PE Ratio	126.67
Forward PE	24.62
PS Ratio	12.84
PB Ratio	20.90
P/TBV Ratio	20.90
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 81.85, with an EV/FCF ratio of -80.83.

EV / Earnings	126.14
EV / Sales	13.15
EV / EBITDA	81.85
EV / EBIT	84.93
EV / FCF	-80.83

Financial Position

The company has a current ratio of 4.02, with a Debt / Equity ratio of 1.07.

Current Ratio	4.02
Quick Ratio	2.91
Debt / Equity	1.07
Debt / EBITDA	4.10
Debt / FCF	-4.17
Interest Coverage	2.10

Financial Efficiency

Return on equity (ROE) is 19.70% and return on invested capital (ROIC) is 9.79%.

Return on Equity (ROE)	19.70%
Return on Assets (ROA)	7.26%
Return on Invested Capital (ROIC)	9.79%
Return on Capital Employed (ROCE)	12.05%
Revenue Per Employee	1.02M
Profits Per Employee	102,902
Employee Count	338
Asset Turnover	0.75
Inventory Turnover	0.41

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.41

Income Statement

In the last 12 months, TG Therapeutics had revenue of EUR 357.48 million and earned 36.22 million in profits. Earnings per share was 0.22.

Revenue	357.48M
Gross Profit	312.53M
Operating Income	55.35M
Pretax Income	38.62M
Net Income	36.22M
EBITDA	55.39M
EBIT	55.35M
Earnings Per Share (EPS)	0.22

Full Income Statement

Balance Sheet

The company has 255.58 million in cash and 235.54 million in debt, giving a net cash position of 20.04 million.

Cash & Cash Equivalents	255.58M
Total Debt	235.54M
Net Cash	20.04M
Net Cash Per Share	n/a
Equity (Book Value)	219.54M
Book Value Per Share	1.51
Working Capital	448.08M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -56.46 million and capital expenditures -64,764, giving a free cash flow of -56.53 million.

Operating Cash Flow	-56.46M
Capital Expenditures	-64,764
Free Cash Flow	-56.53M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 87.43%, with operating and profit margins of 15.48% and 10.13%.

Gross Margin	87.43%
Operating Margin	15.48%
Pretax Margin	10.80%
Profit Margin	10.13%
EBITDA Margin	15.49%
EBIT Margin	15.48%
FCF Margin	n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.66%
Shareholder Yield	-9.66%
Earnings Yield	0.79%
FCF Yield	-1.23%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TG Therapeutics has an Altman Z-Score of 3.66.

Altman Z-Score	3.66
Piotroski F-Score	n/a